Artículos de revistas
Analysis Of The Contribution Of Immunologically-detectable Her2, Steroid Receptors And Of The "triple-negative" Tumor Status To Disease-free And Overall Survival Of Women With Epithelial Ovarian Cancer
Registro en:
Acta Histochemica. Urban Und Fischer Verlag Jena, v. 116, n. 3, p. 440 - 447, 2014.
651281
10.1016/j.acthis.2013.09.010
2-s2.0-84899951186
Autor
De Toledo M.C.S.
Sarian L.O.
Sallum L.F.
Andrade L.L.A.
Vassallo J.
De Paiva Silva G.R.
Pinto G.A.
Soares F.A.
Fonseca C.D.P.P.
Derchain S.F.M.
Institución
Resumen
We assessed associations between steroid receptors including: estrogen-alpha, estrogen-beta, androgen receptor, progesterone receptor, the HER2 status and triple-negative epithelial ovarian cancer (ERα-/PR-/HER2-; TNEOC) status and survival in women with epithelial ovarian cancer. The study included 152 women with primary epithelial ovarian cancer. The status of steroid receptor and HER2 was determined by immunohistochemistry. Disease-free and overall survival were calculated and compared with steroid receptor and HER2 status as well as clinicopathological features using the Cox Proportional Hazards model. A mean follow-up period of 43.6 months (interquartile range = 41.4 months) was achieved where 44% of patients had serous tumor, followed by mucinous (23%), endometrioid (9%), mixed (9%), undifferentiated (8.5%) and clear cell tumors (5.3%). ER-alpha staining was associated with grade II-III tumors. Progesterone receptor staining was positively associated with a Body Mass Index. ≥. 25. Androgen receptor positivity was higher in serous tumors. In stand-alone analysis of receptor contribution to survival, estrogen-alpha positivity was associated with greater disease-free survival. However, there was no significant association between steroid receptor expression, HER2 status, or TNEOC status, and overall survival. Although estrogen-alpha, androgen receptor, progesterone receptor and the HER2 status were associated with key clinical features of the women and pathological characteristics of the tumors, these associations were not implicated in survival. Interestingly, women with TNEOC seem to fare the same way as their counterparts with non-TNEOC. © 2013 Elsevier GmbH. 116 3 440 447 Arias-Pulido, H., Smith, H.O., Joste, N.E., Bocklage, T., Qualls, C.R., Chavez, A., Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors (2009) Gynecol Oncol, 114, pp. 480-485 Chácon, R., Constanzo, M., Triple negative breast cancer (2010) Breast Cancer Res, 12, pp. S3 De Stefano, I., Zannoni, G.F., Prisco, M.G., Fagotti, A., Tortorella, L., Vizzielli, G., Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer (2011) Gynecol Oncol, 122, pp. 573-579 Esfahlan, R.J., Zarghami, N., Esfahlan, A.J., Mollazadeh, M., Nejati, K., Nasiri, M., The possible impact of obesity on androgen, progesterone and estrogen receptors (ERα and ERβ) gene expression in breast cancer patients (2011) Breast Cancer (Auckl), 5, pp. 227-237 García-Velasco, A., Mendiola, C., Richardson, D., Ballestín, C., Colomer, R., Cortés-Funes, H., Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma (2008) Clin Transl Oncol, 10, pp. 367-371 Halon, A., Nowak-Markwitz, E., Maciejczyk, A., Pudelko, M., Gansukh, T., Györffy, B., Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients (2011) Anticancer Res, 31, pp. 711-718 Hecht, J., Kotsopoulos, J., Hankinson, S.E., Tworeger, S.S., Relationship between epidemiological risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study (2009) Cancer Epidemiol Biomarkers Prev, 18, pp. 1624-1632 Hodgall, E.V., Christensen, L., Hodgall, C.K., Blaakaer, J., Bock, J.E., Glud, E., Distribution of HER2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma (2003) Cancer, 98, pp. 66-73 Hodgall, E.V., Christensen, L., Hodgall, C.K., Blaakaer, J., Gayther, S., Jacobs, I.J., Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the "Malova" ovarian cancer study (2007) Oncol Rep, 18, pp. 1051-1059 Hoopmann, M., Sachse, K., Valter, M.M., Becker, M., Neumann, R., Ortmann, M., Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients (2010) Eur J Cancer Care (Engl), 19, pp. 809-815 Kommoss, F., Pfisterer, J., Thome, M., Schafer, W., Sauerbrei, W., Pfleiderer, A., Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects (1992) Gynecol Oncol, 47, pp. 317-322 Lanitis, E., Dangaj, D., Hagemann, I.S., Song, D., Best, A., Sandaltzopoulos, R., Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically - detectable levels (2012) PloS One, 7 (11), pp. e49829 Lee, P., Rosen, D.G., Zhu, C., Silva, E.G., Liu, J., Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer (2005) Gynecol Oncol, 96, pp. 671-677 Lenhard, M., Tereza, L., Heublein, S., Ditsch, N., Himsl, I., Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival (2012) BMC Cancer, 12, pp. 553-570 Liu, N., Wang, X., Sheng, X., The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer (2010) J Clin Pathol, 63, pp. 240-243 Liu, N., Wang, X., Sheng, X., 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis (2011) Curr Opin Obstet Gynecol, 23, pp. 19-23. , [Review] Motamed-Khorasani, A., Jurisica, I., Letarte, M., Shaw, P.A., Parkes, R.K., Zhang, X., Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression (2007) Oncogene, 26, pp. 198-214 Modugno, F., Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review (2004) Am J Epidemiol, 159, pp. 319-335 Nodin, B., Zendehrokh, N., Brändstedt, J., Nilsson, E., Manjer, J., Brennan, D.J., Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival (2010) J Ovarian Res, 17, pp. 3-14 http://www.r-project.org/, R Core Team, 2013. R: A Language and Environment for Statistical ComputingSallum, L.F., Sarian, L.O., Andrade, L.A., Vassallo, J., Soares, F.A., Pinto, G.A., Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status (2013) J. Gynecol. Oncol., 24 (2), pp. 167-176. , [Epub 2013 Apr 5] Schildkraut, J.M., Bastos, E., Berchuck, A., Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer (1997) J Natl Cancer Inst, 89, pp. 932-938 Yang, X.Y., Xi, M.R., Yang, K.X., Yu, H., Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients (2009) Gynecol Oncol, 113, pp. 99-104 Zhao, D., Zhang, F., Zhang, W., He, J., Zhao, Y., Sun, J., Prognostic role of hormone receptors in ovarian cancer. A systematic review and meta-analysis (2013) Int J Gynecol Cancer, 23, pp. 25-33